Ascelia Pharma AB (CHIX:ACES) Cash Flow for Dividends: kr0.00 Mil (TTM As of Mar. 2026)

What is Ascelia Pharma AB Cash Flow for Dividends?

Ascelia Pharma AB CHIX:ACES 28 Cash Flow for Dividends is kr0.00 Mil as of Mar. 2026. GuruFocus rates CHIX:ACES with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

Ascelia Pharma AB's cash flow for dividends for the three months ended in Mar. 2026 was kr0.00 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.00 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Ascelia Pharma AB Cash Flow for Dividends Related Terms

Ascelia Pharma AB Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Ascelia Pharma AB's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascelia Pharma AB Cash Flow for Dividends Chart

Ascelia Pharma AB Annual Data

Trend

Jun17

Jun18

Jun19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Cash Flow for Dividends

Get a 7-Day Free Trial

0.00

Ascelia Pharma AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Cash Flow for Dividends	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

28GF Score

Ascelia Pharma AB CHIX:ACES

Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Ascelia Pharma AB Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

Frequently Asked Questions Learn more about Cash Flow for Dividends →

What does a Cash Flow for Dividends of kr0.00 Mil mean?

Ascelia Pharma AB (CHIX:ACES) has a Cash Flow for Dividends of kr0.00 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Ascelia Pharma AB and its competitors.

Is Ascelia Pharma AB's Cash Flow for Dividends too high?

Ascelia Pharma AB's current Cash Flow for Dividends is kr0.00 Mil. Overall, Ascelia Pharma AB has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.

How does Ascelia Pharma AB's Cash Flow for Dividends compare to VRTX and REGN?

Ascelia Pharma AB's Cash Flow for Dividends of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Cash Flow for Dividends for a Biotechnology company?

A good Cash Flow for Dividends depends on the Biotechnology industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Cash Flow for Dividends mean?

A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Ascelia Pharma AB and its competitors. Ascelia Pharma AB's current Cash Flow for Dividends is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Ascelia Pharma AB stock overvalued right now?

Ascelia Pharma AB (CHIX:ACES) has a current Cash Flow for Dividends of kr0.00 Mil. The current Cash Flow for Dividends is kr0.00 Mil. Ascelia Pharma AB's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Cash Flow for Dividends calculated?

Cash Flow for Dividends is calculated from a company's financial statements. For Ascelia Pharma AB (CHIX:ACES), the current Cash Flow for Dividends is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascelia Pharma AB Business Description

Industry Healthcare Biotechnology

Comparable Companies OSTO:IVACC OSTO:SPRINT OSTO:IMMU OSTO:CLBIO XSAT:CESSA OSTO:CANTA OSTO:ISOFOL OSTO:XBRANE OSTO:NICA OSTO:INIT VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges ACE:Sweden

Address Hyllie Boulevard 34, Malmo, SWE, 215 32

Website https://www.ascelia.com

Ascelia Pharma AB is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. It has two drug candidates, Orviglance and Oncoral, in development. Orviglance (manganese chloride tetrahydrate) is an oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with impaired kidney function, and Oncoral is a novel oral irinotecan tablet in development.

28GF Score

Get the complete analysis for CHIX:ACES

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr3.29

Price

View CHIX:ACES Analysis

See Cash Flow for Dividends data for all stocks →